Clinical Trials

Carcinoma, Oropharyngeal Neoplasms

NCT06806930 2026-03-03

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

Phase 2 Active not recruiting

90 enrolled

Breast

Breast Neoplasms, Carcinoma, Neoplasms

NCT02574728 2026-03-02

AflacST1502

46 enrolled

CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT06595498 2026-03-02

Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

Phase NA Active not recruiting

130 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07441681 2026-03-02

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Not yet recruiting

454 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05063916 2026-02-27

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

18 enrolled

Gynecologic

Carcinoma, Uterine Cervical Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

27 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07408635 2026-02-13

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

GastrointestinalHead & Neck

43 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06027086 2026-02-12

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1/2 Recruiting

27 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00349830 2026-02-10

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Recruiting

2,000 enrolled

Adenocarcinoma, Carcinoma, Neoplasms

NCT05232851 2026-02-10

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Phase 1/2 Completed

20 enrolled

Phase NA Not yet recruiting

Carcinoma, Oropharyngeal Neoplasms

NCT07400263 2026-02-10

Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors

30 enrolled

Carcinoma

NCT06532279 2026-02-02

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

98 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT07257094 2026-01-26

Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer

Recruiting

346 enrolled

Dermatologic

Carcinoma, Carcinoma, Basal Cell, Carcinoma, Squamous Cell

NCT07365124 2026-01-26

MRinRT

Not yet recruiting

165 enrolled

CNSGastrointestinal

Carcinoma, Esophageal Neoplasms, Glioblastoma, Neoplasms, Neurologic Manifestations, Pancreatic Neoplasms, Stomach Neoplasms

NCT04429490 2026-01-21

PESTIPAC

Phase NA Completed

56 enrolled

Phase 3 Enrolling by invitation

Carcinoma

NCT07311057 2026-01-06

Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy

20 enrolled

Phase NA Active not recruiting

Carcinoma, Carcinoma, Squamous Cell

NCT04124198 2025-12-31

QoLATI

138 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, DNA Virus Infections, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Papillomavirus Infections

NCT06612827 2025-12-24

OCAPI

Recruiting

20 enrolled